Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

Abstract

This study provides Class III evidence that in patients with relapsing-remitting multiple sclerosis, natalizumab stabilizes EDSS scores, decreases relapse rates, and is associated with an increased risk of progressive multifocal leukoencephalopathy.